Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital

[1]  L. Risch,et al.  Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies , 2020, Clinical Infectious Diseases.

[2]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[3]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[4]  G. Lippi,et al.  Clinical value of anti‐SARS‐COV‐2 serum IgA titration in patients with COVID‐19 , 2020, Journal of medical virology.

[5]  A. Gylfason,et al.  Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.

[6]  X. Zhang,et al.  Predictive effects of IgA and IgG combination to assess pulmonary exudation progression in COVID‐19 patients , 2020, Journal of medical virology.

[7]  N. Zhong,et al.  Characteristics and roles of severe acute respiratory syndrome coronavirus 2‐specific antibodies in patients with different severities of coronavirus 19 , 2020, Clinical and experimental immunology.

[8]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[9]  Pratik Sinha,et al.  Is a "Cytokine Storm" Relevant to COVID-19? , 2020, JAMA internal medicine.

[10]  Devy M. Emperador,et al.  Antibody tests for identification of current and past infection with SARS‐CoV‐2 , 2020, The Cochrane database of systematic reviews.

[11]  L. García,et al.  Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 , 2020, Frontiers in Immunology.

[12]  Yajuan Li,et al.  Serum IgA, IgM, and IgG responses in COVID-19 , 2020, Cellular & Molecular Immunology.

[13]  O. Rötzschke,et al.  The role of IgA in COVID-19 , 2020, Brain, Behavior, and Immunity.

[14]  H. Hakonarson,et al.  Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients , 2020, European Respiratory Journal.

[15]  B. Posteraro,et al.  Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[17]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[18]  R. José,et al.  COVID-19 cytokine storm: the interplay between inflammation and coagulation , 2020, The Lancet Respiratory Medicine.

[19]  Zhe Zhu,et al.  Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 , 2020, International Journal of Infectious Diseases.

[20]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[21]  Shihua Zhao,et al.  The role of imaging in 2019 novel coronavirus pneumonia (COVID-19) , 2020, European Radiology.

[22]  Amber Dance.  What is a cytokine storm? , 2020 .

[23]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[24]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[25]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[26]  S. Blomqvist,et al.  Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[27]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[28]  Shaoqiang Li,et al.  Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.

[29]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[30]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[31]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[32]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[33]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[34]  M. Tashiro,et al.  IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration , 2018, Human Vaccines & Immunotherapeutics.

[35]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[36]  D. Hui,et al.  Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome , 2005, Journal of Clinical Virology.

[37]  Arul Earnest,et al.  Asymptomatic SARS Coronavirus Infection among Healthcare Workers, Singapore , 2005, Emerging infectious diseases.

[38]  P. Hsueh,et al.  Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.

[39]  O. Tsang,et al.  Natural Course of Severe Acute Respiratory Syndrome-Associated Coronavirus Immunoglobulin after Infection , 2004, The Journal of infectious diseases.

[40]  P. Woo,et al.  Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus , 2004, Clinical Diagnostic Laboratory Immunology.

[41]  D. Dwyer,et al.  Kinetics of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibodies in 271 Laboratory-Confirmed Cases of SARS , 2004, Clinical Diagnostic Laboratory Immunology.

[42]  J. Sung,et al.  Seroprevalence of Antibody to Severe Acute Respiratory Syndrome (SARS)–Associated Coronavirus among Health Care Workers in SARS and Non-SARS Medical Wards , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  O. Tsang,et al.  Asymptomatic Severe Acute Respiratory Syndrome–associated Coronavirus Infection , 2003, Emerging infectious diseases.

[44]  A. Xu,et al.  Profile of specific antibodies to the SARS-associated coronavirus. , 2003, The New England journal of medicine.

[45]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[46]  T. Ichida.  World Medical Association declaration of Helsinki , 1991, Gastroenterologia Japonica.

[47]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[48]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[49]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.